Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort | Zendy

Christopher Teshima | Zendy; Adrienne Thompson | Zendy; LeRose Dhanoa | Zendy; Levinus A. Dieleman | Zendy; Richard N. Fedorak | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-Term Response Rates to Infliximab Therapy for Crohn’s Disease in an Outpatient Cohort

Author(s) -

Christopher Teshima,

Adrienne Thompson,

LeRose Dhanoa,

Levinus A. Dieleman,

Richard N. Fedorak

Publication year - 2009

Publication title -

canadian journal of gastroenterology

Language(s) - English

Resource type - Journals

eISSN - 1916-7237

pISSN - 0835-7900

DOI - 10.1155/2009/180840

Subject(s) - medicine , infliximab , azathioprine , maintenance therapy , crohn's disease , concomitant , adverse effect , rash , retrospective cohort study , inflammatory bowel disease , mercaptopurine , cohort , dosing , disease , psoriasis , surgery , chemotherapy , immunology

Infliximab's efficacy in the induction and maintenance of remission in luminal Crohn's disease has been confirmed by randomized, controlled trials. Less clearly described are long-term outcomes in the clinical practice setting since the establishment of regularly scheduled, every eight-week maintenance infliximab infusions. Existing reports describing clinical practice outcomes are limited by short durations of follow-up or by the use of episodic dosing, or focus on safety data rather than clinical outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research